Sumitomo Pharma Co.

4506.TSE

10.21 USD

-0.67

-6.16%

Overview

Last close

10.21 usd

Market cap

4.06B usd

52 week high

20.84 usd

52 week low

3.42 usd

Target price

13.55 usd

Valuation

P/E

4.3903

Forward P/E

20.202

Price/Sales

1.498

Price/Book Value

2.2179

Enterprise Value

5.28B usd

EV/Revenue

1.8698

EV/EBITDA

5.2742

Key financials

Revenue TTM

2.88B usd

Gross Profit TTM

1.70B usd

EBITDA TTM

824.94M usd

Earnings per Share

2.47 usd

Dividend

N/A usd

Total assets

5.21B usd

Net debt

1.29B usd

About

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.